23051-08-3

Usage

Uses

Used in Chemical Production:
8-hydroxy-2-methylquinoline-7-carboxylic acid is used as a chemical intermediate for the synthesis of various derivatives and compounds in the chemical industry. Its unique structure with a hydroxy substituent and a carboxylic acid group allows for further functionalization and incorporation into more complex molecules.
Used in Research and Development:
8-hydroxy-2-methylquinoline-7-carboxylic acid is used as a research compound for studying the properties and potential applications of hydroquinoline derivatives. Its structure and reactivity can provide insights into the development of new compounds with specific functionalities and applications in various fields.
Used in Pharmaceutical Industry:
8-hydroxy-2-methylquinoline-7-carboxylic acid is used as a potential candidate for the development of new drugs and pharmaceuticals. Its chemical structure may offer opportunities for the design of novel therapeutic agents with specific biological activities and potential applications in medicine.
Used in Material Science:
8-hydroxy-2-methylquinoline-7-carboxylic acid is used as a component in the development of new materials with unique properties. Its chemical structure may contribute to the creation of materials with specific characteristics, such as improved stability, reactivity, or other desirable properties in various applications.

InChI:InChI=1/C11H9NO3/c1-6-2-3-7-4-5-8(11(14)15)10(13)9(7)12-6/h2-5,13H,1H3,(H,14,15)

Upstream product

• 826-81-3 2-methyl-8-quinolinol 
• 124-38-9 carbon dioxide 
• 15719-64-9 methylammonium carbonate 
• 201230-82-2 carbon monoxide 

Downstream Products

• 15599-52-7 5,7-dibromo-2-methylquinolin-8-ol 
• 1030596-35-0 C₁₉H₁₇FN₂O₂ 
• 1006391-83-8 8-hydroxy-2-methylquinoline-7-carboxylic acid [2-(4-fluorophenyl)ethyl]amide 
• 1006391-81-6 8-hydroxy-2-methylquinoline-7-carboxylic acid phenethylamide 
• 1006391-79-2 8-hydroxy-2-methylquinoline-7-carboxylic acid 4-methoxybenzylamide 
• 934611-87-7 8-hydroxy-2-methylquinoline-7-carboxylic acid 4-fluorobenzylamide 
• 1006391-75-8 8-hydroxy-2-methylquinoline-7-carboxylic acid Benzylamide 
• 1030596-43-0 2-hydroxybenzoic acid-N'-(8-hydroxy-2-methylquinoline-7-carbonyl)hydrazide 
• 1006391-77-0 8-hydroxy-2-methylquinoline-7-carboxylic acid 4-methylbenzylamide 
• 1204762-72-0 (E)-2-(3-chloro-4,5-dihydroxystyryl)-8-hydroxyquinoline-7-carboxylic acid 

Relevant academic research and scientific papers

X-ray and molecular modelling in fragment-based design of three small quinoline scaffolds for HIV integrase inhibitors

Crystal structures of three small molecular scaffolds based on quinoline, 2-methylquinoline-5,8-dione, 5-hydroxy-quinaldine-6-carboxylic acid and 8-hydroxy-quinaldine-7-carboxylic acid, were characterised. 5-Hydroxy- quinaldine-6-carboxylic acid was co-crystallized with cobalt(II) chloride to form a model of divalent metal cation-ligand interactions for potential HIV integrase inhibitors. Molecular docking into active site of HIV IN was also performed on 1WKN PDB file. Selected ligand-protein interactions have been found specific for active compounds. Studied structures can be used as scaffolds in fragment-based design of new potent drugs.

Investigation of the antimycobacterial activity of 8-hydroxyquinolines

A series of styrylquinolines and quinolineamides based on the 8-hydroxyquinoline moiety were investigated as potential antimycobacterial agents. The lipophilicity of the compounds was measured using RP-HPLC and the tests of their activity against Mycobacterium kansasii, the M. avium complex, M. smegmatis, M. abscessus, M. tuberculosis and M. avium paratuberculosis was performed. Several of the compounds that were obtained appeared to be more effective than isoniazid and ciprofloxacin. The 5,7-dinitro-8-hydroxyquinoline derivative possessed the highest potency against M. abscessus and M. Smegmatis, which was about twice as effective as ciprofloxacin, while 2-(2-hydroxystyryl)-8-hydroxyquinoline-7-carboxylic acid appeared to be comparable with the standard drugs that are against the M. avium complex. The structure activity relationships are discussed.

Synthesis, spectroscopy and computational studies of selected hydroxyquinoline carboxylic acids and their selected fluoro-, thio-, and dithioanalogues

The faster and more efficient new synthetic methodologies of crystalline hydroxyquinoline carboxylic acids and their fluoro-, thio- and dithioanalogues were elaborated. The FTIR, multinuclear NMR, UV-Vis and single crystal X-ray characteristics of the series of quinoline carboxylic acids have been determined experimentally and rationalized on the basis of DFT calculation method with B3LYP functional.

Styrylquinolines, their process of preparation and their therapeutic uses

The present invention concerns new substituted styrylquinolines, their process of preparation and their therapeutic uses as integrase inhibitors and/or for the treatment and/or prevention of HIV.

Investigating biological activity spectrum for novel quinoline analogues 2: Hydroxyquinolinecarboxamides with photosynthesis-inhibiting activity

Two series of amides based on quinoline scaffold were designed and synthesized in search of photosynthesis inhibitors. The compounds were tested for their photosynthesis-inhibiting activity against Spinacia oleracea L. and Chlorella vulgaris Beij. The com

Quinoline derivatives, having in particular antiviral properties, preparation and biological applications thereof

The invention concerns quinoline derivatives of formula (I) in which: Ra, Rband Rc, identical or different represent one or several substituents, themselves identical or different, in any position on the cycles, this or th

8-hydroxy-7-substituted quinolines as anti-viral agents

The present invention provides for 8-hydroxy-7-substituted quinoline compounds such as formula III These compounds are useful as anti-viral agents. Specifically, these compounds have anti-viral activity against the herpes virus, cytomegalovirus (CMV). Many of these compounds are also active against other herpes viruses, such as the varicella zoster virus, the Epstein-Barr virus, the herpes simplex virus and the human herpes virus type 8 (HHV-8).

Styrylquinoline derivatives: A new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells

On the basis of the fact that several polynucleotidyl transferases, related to HIV integrase, contain in their active site two divalent metal cations, separated by ca. 4 ?, new potential HIV integrase inhibitors were designed, in which a quinoline substructure is linked to an aryl nucleus possessing various hydroxy substitution patterns, by means of an ethylenic spacer. Although the most active compounds contain the catechol structure, this group is not essential for the activity, since compound 21 that lacks such a moiety is a potent drug, implicating the presence of a different pharmacophore. The most promising styrylquinolines thus synthesized inhibit HIV-1 integrase in vitro at micromolar or submicromolar concentrations and block HIV replication in CEM cells, with no significant cellular toxicity in a 5-day period assay. These inhibitors are active against integrase core domain-mediated disintegration, suggesting that fragment 50-212 is their actual target. These new styrylquinolines may provide lead compounds for the development of novel antiretroviral agents for AIDS therapeutics, based upon inhibition of HIV integrase. They might also be used in the elucidation of the mechanism of inhibition of this enzyme; e.g., they could serve as candidates for cocrystallization studies with HIV integrase.